Eli Lilly & Co.

Pharmaceuticals
United States
Earnings Per Share Growth (%)1.35%
Cost of Goods Sold (US$ Millions)$5,037
Current Liabilities (US$ Millions)$8,230
Total Assets (US$ Millions)$12,574
Long Term Debt$7,972
Return on Equity15.67%
Revenue (US$ Millions)$19,959
Total Company Assets$35,569
Revenue Growth (%)1.75%
Net Income (US$ Millions)$2,408
Earnings Per Share (US$)$1.35
Total Equity (US$ Millions)$14,571
Profit Margin (%)12.07%
Debt To Equity Ratio (%)0.55%
Inventory Turnover$3,446